Literature DB >> 9552013

The role of infection in COPD.

R Wilson1.   

Abstract

Clinical studies of acute exacerbations of COPD are difficult because of the heterogeneous nature of COPD, diffuse symptoms that can vary spontaneously, and difficulties in defining clinical response both in the short and long term. The role of bacterial infection, and thus use of antibiotics, in COPD is controversial. The available evidence shows that bacterial infection has a significant role in acute exacerbations, but its role in disease progression is less certain. Upper respiratory tract commensals, such as nontypable Haemophilus influenzae, cause most bronchial infections by exploiting deficiencies in the host defenses. Some COPD patients are chronically colonized by bacteria between exacerbations, which represents an equilibrium in which the numbers of bacteria are contained by the host defenses but not eliminated. When an exacerbation occurs, this equilibrium is upset and bacterial numbers increase, which incites an inflammatory response. Neutrophil products can further impair the mucosal defenses, favoring the bacteria, but if the infection is overcome, symptoms resolve. However, if the infection persists, chronic inflammation may cause lung damage. About half of exacerbations involve bacterial infection, but these patients are not easy to differentiate from those who are uninfected, which means that antibiotics have to be given more often than is strictly necessary. Further research is needed to characterize those patients in whom bacterial infection has a more important role.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9552013     DOI: 10.1378/chest.113.4_supplement.242s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis.

Authors:  T F Murphy; C Kirkham; E DeNardin; S Sethi
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Christoph Aebi; Sanjay Sethi
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response.

Authors:  Timothy F Murphy; Aimee L Brauer; Brydon J B Grant; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

Review 4.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 5.  [Alpha 1-protease inhibitor deficiency. Diagnosis, follow-up and therapy options].

Authors:  T Köhnlein; H Klein; T Welte
Journal:  Med Klin (Munich)       Date:  1999-07-15

6.  Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Christoph Aebi; Sanjay Sethi
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  Conservation of outer membrane protein E among strains of Moraxella catarrhalis.

Authors:  T F Murphy; A L Brauer; N Yuskiw; E R McNamara; C Kirkham
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

8.  Antimicrobials in acute exacerbations of chronic obstructive pulmonary disease - An analysis of the time to next exacerbation before and after the implementation of standing orders.

Authors:  Rob D Goddard; Shelly A McNeil; Kathryn L Slayter; R Andrew McIvor
Journal:  Can J Infect Dis       Date:  2003-09

Review 9.  Chronic obstructive pulmonary disease.

Authors:  J M Madison; R S Irwin
Journal:  Lancet       Date:  1998-08-08       Impact factor: 79.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.